Aptuit extends GSK partnership at Italian site


Aptuit and GlaxoSmithKline ($GSK) have agreed to extend their partnership for another two years, a move Aptuit says is a validation of its drug discovery efforts.

The relationship began back in 2010, when Aptuit bought GSK's Verona, Italy, pharmaceutical research center, transforming it into The Aptuit Center for Drug Discovery & Development, the company said. The two worked together after the sale, and GSK re-upping demonstrates the value of Aptuit's discovery services, Chairman Timothy Tyson said.

"Aptuit initiatives in Verona, such as Lean Six Sigma, are resulting in productivity benefits across our business lines," Tyson said in a statement. "The high level of quality and regulatory compliance demonstrated in our work has been noticeable to the more than 200 customers who have visited the site since 2010."

Aptuit has doubled down on its discovery and development operations since selling its clinical trial supply business to Catalent for $410 million last year.

- read the release

Related Articles:
Catalent snaps up Aptuit's trial supplies ops for $410M
GSK bets that hungry spinouts can upstage fat pharma
GSK aims for biotech attitude at R&D ops

Filed Under